Jamie Wilkins | Head- Risk Management Center of Excellence- Worldwide Safety
Pfizer

Jamie Wilkins, PharmD, is a leading global expert in pharmacovigilance, risk management and global safety policy, with a robust background as a regulator at the US FDA and in the pharmaceutical industry.

Dr. Wilkins holds a Doctor of Pharmacy degree from the University of Maryland School of Pharmacy and has dedicated her career to advancing drug safety through innovative pharmacovigilance and risk management strategies. Currently, Dr. Wilkins serves as the Head of the Risk Management Center of Excellence and Secretariat of the Pharmacovigilance Policy Committee at Pfizer, Inc. where she is instrumental in shaping global safety policies and overseeing global risk management strategy, operations and compliance.

In addition to her expertise in pharmacovigilance, Dr. Wilkins is passionately involved in educational initiatives aimed at enhancing pharmaceutical practices in low- and middle-income countries (LMICs). She manages global medical grant programs designed to build local capacity, improve drug safety practices, and foster knowledge sharing in these regions. Dr. Wilkins is an active contributor and steering committee member to the IFPMA-BeCOME (Beyond COvid Monitoring Excellence) initiative, where she works to influence global safety standards and advocate for evolution of pharmacovigilance and pharmacoepidemiology solutions worldwide. In addition, she sits on the board of directors for the REMS Industry Consortium (RIC), and leads a joint US FDA/Pfizer Fellowship Program in Risk Management.

Jamie is additionally a well-respected global presenter, moderator, and panel member. Further, she is a two-time winner of the Frances O. Kelsey Drug Safety Award (highest safety award at the US FDA), as well as the Pfizer R&D Quality award in 2022. Her dedication to improving global health through excellence, education and policy has established her as a respected leader in the field.